Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 18:18:1435922.
doi: 10.3389/or.2024.1435922. eCollection 2024.

Tumor therapeutics in the era of "RECIST": past, current insights, and future prospects

Zhilong Xu  1 , Gening Jiang  1 , Jie Dai  1
Affiliations
Review

Tumor therapeutics in the era of "RECIST": past, current insights, and future prospects

Zhilong Xu et al. Oncol Rev. .

Abstract

In recent years, advancements in medical treatment and imaging technologies have revolutionized the assessment of tumor response. However, the Response Evaluation Criteria in Solid Tumors (RECIST) has long been established as the gold standard for evaluating tumor treatment. As treatment modalities evolve, the need for continuous refinement and adaptation of RECIST becomes increasingly apparent. This review explores the historical evolution, current applications, limitations, and future directions of RECIST. It discusses the challenges of distinguishing true progression from pseudo-progression in ICIs (immune checkpoint inhibitors), the integration of advanced imaging tools, and the necessity for RECIST criteria tailored to specific therapies like neoadjuvant treatments. The review highlights the ongoing efforts to enhance RECIST's accuracy and reliability in clinical decision-making and the potential for developing new standards to better evaluate treatment efficacy in the rapidly evolving landscape of oncology.

Keywords: artificial intelligence (AI); immune checkpoint inhibitors (ICIs); liquid biopsy; response evaluation criteria in solid tumors (RECIST); tumor imaging.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Simplified assessment workflow of RECIST criteria and methodology for overall status evaluation.
FIGURE 2
FIGURE 2
Number of CTC-related studies registered on the National Institutes of Health website (as of March 2024).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zettler M, Basch E, Nabhan C. Surrogate end points and patient-reported outcomes for novel oncology drugs approved between 2011 and 2017. JAMA Oncol (2019) 5(9):1358–9. 10.1001/jamaoncol.2019.1760 - DOI - PMC - PubMed
    1. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 30(21):2684–90. 10.1200/jco.2011.36.4752 - DOI - PMC - PubMed
    1. Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics (2015) 35(2):424–37. 10.1148/rg.352140121 - DOI - PubMed
    1. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res (2017) 23(8):1920–8. 10.1158/1078-0432.ccr-16-1741 - DOI - PubMed
    1. Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol (2018) 15(12):748–62. 10.1038/s41571-018-0111-2 - DOI - PubMed

Grants and funding

The authors declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by Shanghai Pulmonary Hospital Fund (fkcx2305) and the National Natural Science Foundation of China (Grant No.82172848).

LinkOut - more resources